Jazz Pharmaceuticals (JAZZ) Short term Debt (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Short term Debt of $1.0 billion for Q1 2026, up 3224.19% year-over-year from $31.0 million in Q1 2025, and little changed quarter-over-quarter from $1.0 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Short term Debt (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Short term Debt history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.
- In Q1 2026, Short term Debt rose 3224.19% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 3224.19% YoY), while the FY2025 annual figure was $1.0 billion, up 3222.26% from the prior year.
- Short term Debt for Q1 2026 stood at $1.0 billion, roughly flat from $1.0 billion in the prior quarter.
- The five-year high for Short term Debt was $1.0 billion in Q1 2026, with the low at $31.0 million in Q1 2022.
- The 5-year median for Short term Debt is $31.0 million (2022), against an average of $401.0 million.
- The sharpest annual moves came in 2025 and 2026: Short term Debt sank 94.88% in 2025, then jumped 3224.19% in 2026.
- Jazz Pharmaceuticals' Short term Debt stood at $31.0 million in 2022, then jumped by 1851.46% to $605.0 million in 2023, then sank by 94.88% to $31.0 million in 2024, then surged by 3222.26% to $1.0 billion in 2025, then climbed by 0.06% to $1.0 billion in 2026.
- Business Quant data shows JAZZ's Short term Debt at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.02 Bn |
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | 1.03 Bn |
| Sep 30, 2025 | 1.03 Bn |
| Jun 30, 2025 | 1.03 Bn |
| Mar 31, 2025 | 31.00 Mn |
| Dec 31, 2024 | 31.00 Mn |
| Sep 30, 2024 | 31.00 Mn |
| Jun 30, 2024 | 605.80 Mn |
| Mar 31, 2024 | 605.38 Mn |
| Dec 31, 2023 | 604.95 Mn |
| Sep 30, 2023 | 604.51 Mn |
| Jun 30, 2023 | 31.00 Mn |
| Mar 31, 2023 | 31.00 Mn |
| Dec 31, 2022 | 31.00 Mn |
| Sep 30, 2022 | 31.00 Mn |
| Jun 30, 2022 | 31.00 Mn |
| Mar 31, 2022 | 31.00 Mn |
| Dec 31, 2021 | 31.00 Mn |
| Sep 30, 2021 | 31.00 Mn |